Breast Cancer Research and Treatment

, Volume 52, Issue 1–3, pp 99–111 | Cite as

The urokinase plasminogen activator system as a target for prognostic studies in breast cancer

  • Ross W. Stephens
  • Nils Brünner
  • Fritz Jänicke
  • Manfred Schmitt


The identification of patients at high risk of relapse is currently one of the most important issues in breast cancer research. However, the selection of high-risk patients continues to be difficult due to the unpredictable course of this disease. Axillary lymph node status is currently recognized as the best clinical discriminant between good and poor prognosis, yet almost 30% of node- negative patients and 65% of node-positive patients will experience a relapse. Additional prognostic markers are therefore urgently needed.

Since metastatic disease is the main cause of cancer patient morbidity and mortality, the measurement of molecules functionally involved in the regulation of tumor invasion and metastasis is attractive as a means to predict prognosis.

Cancer invasion is a complex process in which degradation of the extracellular matrix plays a crucial role. This degradation is accomplished by the concerted action of several proteolytic enzyme systems, including generation of plasmin by the urokinase pathway of plasminogen activation, matrix metallo-proteases, and other extracellular proteases. Increased expression and secretion of urokinase plasminogen activator (uPA) strongly correlates with the malignant phenotype of many types of cells, and the central role of uPA in tumor invasion is now well established.

This review will focus on the prognostic impact of components of the urokinase plasminogen activation system in breast cancer with emphasize on methodological issues.

prognostic factor trials statistical methods urokinase plasminogen activator system PAI-1 PAI-2 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pedersen AN, Høyer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K, Stephens RW: The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. J Immun Methods 203:55-65, 1997Google Scholar
  2. 2.
    Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WL, Look MP, Klijn JG, Kramer MD: Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55:1423-1427, 1995Google Scholar
  3. 3.
    Danø K, Behrendt N, Brünner N, Ellis V, Plough M, Pyke C: The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8:204-215, 1994Google Scholar
  4. 4.
    Høyer-Hansen G, Rønne E, Solberg H, Behrendt N, Plough M, Lund LR, et al: Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 267:18224-18229, 1992Google Scholar
  5. 5.
    Solberg H, Rømer J, Brünner N, Holm A, Sidenius N, Danø K, Høyer-Hansen G: A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer 58:877-881, 1994Google Scholar
  6. 6.
    Grøndahl-Hansen J, Peters HA, van Putten WLJ, Look MP, Pappot H, Rønne E, Danø K, Klijn JGM, Brünner N, Foekens JA: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1:1079-1087, 1995Google Scholar
  7. 7.
    Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJAG, Høyer-Hansen G, Rønne E, Dybkjaer E, Danø K, Brünner N: ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43:1868-1876, 1997Google Scholar
  8. 8.
    Pedersen N, Schmitt M, Rønne E, Nicoletti MI, Høyer-Hansen G, Conese M, et al: A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 92:2160-2167, 1993Google Scholar
  9. 9.
    Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HR: Tissue type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 48:1348-1349, 1988Google Scholar
  10. 10.
    Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H: Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4:69-78, 1990Google Scholar
  11. 11.
    Jänicke F, Schmitt M, Ulm K, Gössner W, Graeff H: Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet ii(8670):1049, 1989Google Scholar
  12. 12.
    Jänicke F, Schmitt M, Graeff H: Both uPA and PAI-1 are independent prognosticators of relapse and death in breast cancer. In: Glas-Greenwalt P (ed) Fibrinolysis in Disease. CRC Press, Boca Raton, pp 19-25Google Scholar
  13. 13.
    Romain S, Spyratos F, Laine-Bidron C, Bouchet C, Guirou O, Martin PM, Oglobine J, Magdelenat H: Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues. Eur J Clin Chem Clin Biochem 33:603-608, 1995Google Scholar
  14. 14.
    Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H: Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor type 1. Cancer Res 54:2527-2530, 1994Google Scholar
  15. 15.
    Bouchet Bernet C, Spyratos F, Andrieu C, Deytieux S, Becette V, Oglobine J: Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues. Breast Cancer Res Treat 41:141-146, 1996Google Scholar
  16. 16.
    Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong, independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208, 1993Google Scholar
  17. 17.
    Benraad TJ, Geurts-Moespot J, Grøndahl-Hansen J, Schmitt M, Heuvel JJTM, de Witte JH, Foekens JA, Leake RE, Brünner N, Sweep CGJ: Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 workshop. Eur J Cancer 32A:1371-1381, 1996Google Scholar
  18. 18.
    Grebenschikov N, Geurts-Moespot A, De Witte H, Heuvel J, Leake R, Sweep F, Benraad T: A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers 12:6-14, 1997Google Scholar
  19. 19.
    Grøndahl-Hansen J, Agerlin N, Munkholm-Larsen P, Nielsen LS, Dombernowsky P, Danø K: Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 111:42-51, 1988Google Scholar
  20. 20.
    Heinert G, Kirchheimer JC, Christ G, Pfluger H, Binder BR: Plasma urokinase-type plasminogen activator correlates to bone scintigraphy in prostate cancer. Eur Urol 15:256-258, 1988Google Scholar
  21. 21.
    Koelbl H, Kirchheimer JC, Tatra G, Christ G, Binder BR: Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer. Obstet Gynecol 72:252-256, 1988Google Scholar
  22. 22.
    Saito K, Nagashima M, Iwata M, Hamada H, Sumiyoshi K, Takada Y, Takada A: The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors. Thromb Res 58:355-366, 1990Google Scholar
  23. 23.
    Leung KC, Tung Y, Ali M, Lau WN: Measurement of urokinase-type plasminogen activator activity in sera of nasopharyngeal carcinoma patients by an immunocapture assay. Cancer Lett 58:233-240, 1991Google Scholar
  24. 24.
    Huber K, Kirchheimer JC, Sedlmayer A, Bell C, Ermler D, Binder BR: Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen. Cancer Res 53:1788-1793, 1993Google Scholar
  25. 25.
    von Tempelhoff GF, Heilmann L, Dietrich M, Schneider D, Niemann F, Hommel G: Plasmatic plasminogen activator inhibitor activity in patients with primary breast cancer. Thrombosis and Haemostasis 77:606-608, 1997Google Scholar
  26. 26.
    Nielsen HJ, Pappot H, Christensen IJ, Brünner N, Thorlacius-Ussing O, Moesgaard F, Danø K, Grøndahl-Hansen J: Association between plasma PAI-1 and survival in patients with colorectal cancer. Br Med J, in pressGoogle Scholar
  27. 27.
    Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Danø K, Brünner N: Identification of high-risk patients in early-stage colorectal cancer by measurement of plasma urokinase receptor. SubmittedGoogle Scholar
  28. 28.
    Gray RJ: Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc 87:942-951, 1992Google Scholar
  29. 29.
    Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, Jänicke F, Graeff H: Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1, and steroid hormone receptor status in primary breast cancer. Br J Cancer 76:306-311, 1997Google Scholar
  30. 30.
    Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50:6827-6829, 1990Google Scholar
  31. 31.
    Bouchet C, Spyratos F, Martin P M, Hacene K, Gentile A, Oglobine J: Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69:398-405, 1994Google Scholar
  32. 32.
    Foekens JA, Schmitt M, van P W, Peter HA, Bontenbal M, Janicke F, Klijn JG: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52:6101-6105, 1992Google Scholar
  33. 33.
    Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53:2513-2521, 1993Google Scholar
  34. 34.
    Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N: Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clinical Cancer Res 3:233-239, 1997Google Scholar
  35. 35.
    Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208, 1993Google Scholar
  36. 36.
    Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero-Pous M, Deytieux S, Le DV, Tubiana-Hulin M, Brunet M: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84:1266-1272, 1992Google Scholar
  37. 37.
    Fernö M, Bendahl P-O, Borg Å, Brundell J, Hirschberg L, Olsson H, Killander D: Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 32A:793-801, 1996Google Scholar
  38. 38.
    Jänicke F, Schmitt M, Graeff H: Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemostasis 17:303-312, 1991Google Scholar
  39. 39.
    Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Janicke F, Klijn JG: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648-1658, 1994Google Scholar
  40. 40.
    Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ: Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61:597-600, 1995Google Scholar
  41. 41.
    Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S: Plasminogen activator system in human breast cancer. Int J Cancer 50:345-348, 1992Google Scholar
  42. 42.
    Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG: Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87:751-756, 1995Google Scholar
  43. 43.
    Thomssen C, Oppelt P, Jänicke F, Ulm K, Harbeck N, Höfler H, Graeff H, Schmitt M: Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Anticancer Research 1998, in pressGoogle Scholar
  44. 44.
    Clark GM: Integrating prognostic factors. Breast Cancer Res Treat 22:187-191, 1992Google Scholar
  45. 45.
    Sweep CGJ, Geurts-Moespot J, Grebenschikov N, de Witte JH, Heuvel JJTM, Schmitt M, Duffy MJ, Jänicke F, Kramer MD, Foekens JA, Brünner N, Brugal G, Pedersen AN, Benraad TJ: External quality assessment of trans-European multicentre antigen determinations (ELISA) of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) in human breast cancer tissue extracts. British J Cancer, in pressGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Ross W. Stephens
  • Nils Brünner
  • Fritz Jänicke
  • Manfred Schmitt

There are no affiliations available

Personalised recommendations